The results indicate that RSK2 overexpression was statistically associated with the OS rate of breast cancer patients (pooled HR = 0.71, 95% CI: 0.48–0.94, Cochran’s Q test p = 0.95, I2 = 0.0%) (Figure 5A), while there was no significant relationship between RSK2 expression and DFS (pooled HR = 0.96, 95% CI: 0.63–1.29, Cochran’s Q test p = 0.94, I2 = 0.0%) (Figure 5B). The gene discussed is RPS6KA3; the disease is breast cancer.